PCI-24781 in Combination With Doxorubicin to Treat Sarcoma

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-28

Study Completion Date

2015-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine the safety and maximum tolerated dose of PCI-24781 that can be given safely with doxorubicin (phase I) and the safety and efficacy of PCI-24781 when used in combination with doxorubicin (phase II) in patients with advanced sarcomas. The study drug, PCI-24781, is believed to regulate genes involved in tumor cell growth. The other study drug, doxorubicin, is considered a standard chemotherapeutic treatment for advanced sarcoma patients. We hypothesize that combining PCI-24781 with doxorubicin can overcome chemoresistance to doxorubicin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine

NCT00753714

Non Small Cell Lung Cancer

COMPLETED PHASE2

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

NCT00258739

Lung Neoplasms

COMPLETED PHASE2

Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

NCT00714246

Non Small Cell Lung Cancer

TERMINATED PHASE1

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

NCT01418001

Sarcoma Leiomyosarcoma Malignant Peripheral Nerve Sheath Tumor +2 more

TERMINATED PHASE1/PHASE2

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung Cancer

NCT01792479

Non-small Cell Lung Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* In the phase I portion of the study, since we are looking for the highest dose of PCI-24781 that can be administered safely without severe or unmanageable side effects in participants that have advanced sarcoma, not everyone who participates in this research study will receive the same dose of PCI-24871.
* Each treatment cycle is 3 weeks (21 days). Participants will take capsules of PCI-24871 for five consecutive days starting on Day 1 of each 3 week cycle. On Day 4 of each cycle, participants will come to the clinic to receive doxorubicin intravenously.
* At specific time intervals, participants will return to the clinic for the following tests and procedures: physical examination, vital signs, blood tests, urine test, EKG, assessment of the tumor by CT scan, and an ECHO or MUGA.
* Participants may remain on the study for a maximum of 6 cycles (about 4-5 months). After the last cycle, as long as the participant is showing benefit, they may elect to continue taking PCI-24781 alone, in which case they will continue in this research study until there is evidence of their tumor growing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PCI-24781 without mandated GCSF

PCI-24781 in combination with doxorubicin without mandated GCSF

Group Type EXPERIMENTAL

PCI-24781

Intervention Type DRUG

Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle

Doxorubicin

Intervention Type DRUG

Administered intravenously on Day 4 of each 3 week cycle

GCSF

Intervention Type DRUG

Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2

PCI-24781 with mandated GCSF

PCI-24781 in combination with doxorubicin with mandated GCSF

Group Type EXPERIMENTAL

PCI-24781

Intervention Type DRUG

Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle

Doxorubicin

Intervention Type DRUG

Administered intravenously on Day 4 of each 3 week cycle

GCSF

Intervention Type DRUG

Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PCI-24781

Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle

Intervention Type DRUG

Doxorubicin

Administered intravenously on Day 4 of each 3 week cycle

Intervention Type DRUG

GCSF

Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

PCI24781 Adriamycin Neupogen

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants must have histologically confirmed metastatic or unresectable sarcoma
* All participants must have received no more than a lifetime cumulative maximum dose of 300 mg/m2 or less of prior doxorubicin and no other anthracycline therapy.
* Participants must have measurable disease, defined as at least one unirradiated lesion that can be accurately measured in at least one dimension as 20mm or greater with conventional techniques or as 10mm or greater with spiral CT scan.
* ECOG performance status of 2 or less
* Ability to swallow oral capsules without difficulty
* Participants must have normal organ and marrow function as outlined in the protocol.
* Women of childbearing potential must have a negative serum/urine pregnancy test within 7 days prior to receiving the first dose of PCI-24781.
* An ECHO or MUGA demonstrating EF \> 50% is required within 4 weeks prior to study drug administration.
* 18 years of age or older

Exclusion Criteria

* Participants who have had immunotherapy, chemotherapy, experimental therapy or radiotherapy within 4 weeks before first day of study drug dosing or those who have not recovered to grade 1 or baseline from adverse events due to agents administered more than 4 weeks earlier.
* Participants who have previously received \> 300 mg/m2 cumulative lifetime dose of doxorubicin, or who have received any other anthracycline chemotherapy.
* Major surgery within 4 weeks before first day of study drug dosing
* Participants with known central nervous system/brain metastases
* Participants receiving chronic corticosteroids \> 20 mg prednisone equivalent per day for \> 7 consecutive days (Topical, inhaled or nasal corticosteroids are permitted).
* Participants with any documented malabsorption syndromes or other conditions that may impair the absorption of PCI-24781 capsules.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Participants requiring concurrent therapeutic anticoagulation or have received therapeutic anticoagulation within 2 weeks of the first day of dosing.
* Risk factors for Torsades de Pointes, or use, within 4 weeks of starting study drug administration, of medications known to prolong QTc interval or that may be associated with Torsades de Pointes.
* QTc prolongation or other significant ECG abnormalities defined as 2nd degree AV block type II, 3rd degree AV block, or bradycardia.
* History of myocardial infarction, acute coronary syndromes, coronary angioplasty and/or coronary artery stenting within the past 6 months.
* For patients with history of major coronary artery disease in the judgement of the responsible physician, a cardiac stress test that demonstrates clinically significant abnormalities when performed within 28 days of first dose of study drug
* Pregnant or breastfeeding women
* Women of childbearing potential, or sexually active men unwilling to use adequate contraceptive protection during the course of the study
* HIV-positive individuals
* Other medical or psychiatric illness or organ dysfunction that, in the opinion of the investigator, would either compromise the patient's safety or interfere with the evaluation of the safety of PCI-24781

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No